Low thrombin inactivation capacity is associated with an increased risk of recurrent ischemic events after ischemic stroke at a young age.

IF 5.5 2区 医学 Q1 HEMATOLOGY
Janneke P Spiegelenberg, Romy De Laat-Kremers, Mark Roest, Bas de Laat, Marleen M H J van Gelder, Anil M Tuladhar, Saskia Middeldorp, Frank-Erik de Leeuw, Jenneke Leentjens
{"title":"Low thrombin inactivation capacity is associated with an increased risk of recurrent ischemic events after ischemic stroke at a young age.","authors":"Janneke P Spiegelenberg, Romy De Laat-Kremers, Mark Roest, Bas de Laat, Marleen M H J van Gelder, Anil M Tuladhar, Saskia Middeldorp, Frank-Erik de Leeuw, Jenneke Leentjens","doi":"10.1016/j.jtha.2024.12.002","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Patients with ischemic stroke at a young age (18-50 years) have an increased long-term risk of recurrent ischemic events. Hypercoagulability may contribute to this high risk.</p><p><strong>Objectives: </strong>To investigate associations between in and ex vivo hemostatic parameters and recurrent ischemic events after an ischemic stroke or transient ischemic attack at a young age.</p><p><strong>Methods: </strong>We included patients with ischemic stroke or TIA between 1980 and 2010 from the prospective FUTURE cohort. Blood samples were collected in 2010 and patients were followed for recurrent ischemic events from 2010 to 2023. Pro- and anticoagulant markers and thrombin generation assay were measured. Thrombin dynamic analysis was used to study underlying pro- and anticoagulant processes. Hazard ratios (HR) per standard deviation increase were assessed with cause-specific hazard models.</p><p><strong>Results: </strong>Of the initial cohort of 581 patients, 332 were eligible. The median time between the index event and 2010 was 7.6 years. During a mean follow-up of 6.5 years, 70 of 332 (21.1%) patients experienced a recurrent ischemic event. Lower antithrombin levels (adjusted HR=0.77; 95% CI 0.60-0.98) and higher fibrinogen levels (HR=1.35; CI 1.04-1.73) were associated with higher risk of recurrent ischemic events. Plasma thrombin generation was not associated with recurrence. However, the thrombin decay constant (HR=0.67; CI 0.51-0.87) was associated with a lower risk of recurrent ischemic events.</p><p><strong>Conclusion: </strong>After an ischemic stroke or TIA at a young age, thrombin decay constant, reflecting reduced protection against thrombin (low antithrombin) and decreased potential to inhibit thrombin (high fibrinogen), is associated with recurrent ischemic events.</p>","PeriodicalId":17326,"journal":{"name":"Journal of Thrombosis and Haemostasis","volume":" ","pages":""},"PeriodicalIF":5.5000,"publicationDate":"2024-12-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Thrombosis and Haemostasis","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.jtha.2024.12.002","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"HEMATOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Patients with ischemic stroke at a young age (18-50 years) have an increased long-term risk of recurrent ischemic events. Hypercoagulability may contribute to this high risk.

Objectives: To investigate associations between in and ex vivo hemostatic parameters and recurrent ischemic events after an ischemic stroke or transient ischemic attack at a young age.

Methods: We included patients with ischemic stroke or TIA between 1980 and 2010 from the prospective FUTURE cohort. Blood samples were collected in 2010 and patients were followed for recurrent ischemic events from 2010 to 2023. Pro- and anticoagulant markers and thrombin generation assay were measured. Thrombin dynamic analysis was used to study underlying pro- and anticoagulant processes. Hazard ratios (HR) per standard deviation increase were assessed with cause-specific hazard models.

Results: Of the initial cohort of 581 patients, 332 were eligible. The median time between the index event and 2010 was 7.6 years. During a mean follow-up of 6.5 years, 70 of 332 (21.1%) patients experienced a recurrent ischemic event. Lower antithrombin levels (adjusted HR=0.77; 95% CI 0.60-0.98) and higher fibrinogen levels (HR=1.35; CI 1.04-1.73) were associated with higher risk of recurrent ischemic events. Plasma thrombin generation was not associated with recurrence. However, the thrombin decay constant (HR=0.67; CI 0.51-0.87) was associated with a lower risk of recurrent ischemic events.

Conclusion: After an ischemic stroke or TIA at a young age, thrombin decay constant, reflecting reduced protection against thrombin (low antithrombin) and decreased potential to inhibit thrombin (high fibrinogen), is associated with recurrent ischemic events.

凝血酶失活能力低与年轻时缺血性中风后复发缺血性事件的风险增加有关。
背景:年轻缺血性卒中患者(18-50 岁)发生复发性缺血性事件的长期风险增加。高凝状态可能是造成这种高风险的原因之一:研究体内外止血参数与年轻时缺血性中风或短暂性脑缺血发作后复发性缺血事件之间的关系:我们纳入了前瞻性 FUTURE 队列中 1980 年至 2010 年间的缺血性中风或 TIA 患者。我们在 2010 年采集了患者的血样,并在 2010 年至 2023 年期间对患者的复发性缺血事件进行了随访。测量了促凝和抗凝标记物以及凝血酶生成测定。凝血酶动态分析用于研究潜在的促凝和抗凝过程。通过特定病因危险模型评估了每标准差增加的危险比(HR):在最初的 581 例患者中,有 332 例符合条件。从指数事件发生到 2010 年的中位时间为 7.6 年。在平均 6.5 年的随访期间,332 名患者中有 70 人(21.1%)再次发生了缺血事件。较低的抗凝血酶水平(调整后HR=0.77;95% CI 0.60-0.98)和较高的纤维蛋白原水平(HR=1.35;CI 1.04-1.73)与较高的复发性缺血事件风险相关。血浆凝血酶生成与复发无关。然而,凝血酶衰变常数(HR=0.67;CI 0.51-0.87)与较低的缺血性事件复发风险相关:结论:年轻时发生缺血性脑卒中或 TIA 后,凝血酶原衰变常数反映了对凝血酶的保护能力降低(抗凝血酶低)和抑制凝血酶的潜力降低(纤维蛋白原高),与缺血性事件的复发有关。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Journal of Thrombosis and Haemostasis
Journal of Thrombosis and Haemostasis 医学-外周血管病
CiteScore
24.30
自引率
3.80%
发文量
321
审稿时长
1 months
期刊介绍: The Journal of Thrombosis and Haemostasis (JTH) serves as the official journal of the International Society on Thrombosis and Haemostasis. It is dedicated to advancing science related to thrombosis, bleeding disorders, and vascular biology through the dissemination and exchange of information and ideas within the global research community. Types of Publications: The journal publishes a variety of content, including: Original research reports State-of-the-art reviews Brief reports Case reports Invited commentaries on publications in the Journal Forum articles Correspondence Announcements Scope of Contributions: Editors invite contributions from both fundamental and clinical domains. These include: Basic manuscripts on blood coagulation and fibrinolysis Studies on proteins and reactions related to thrombosis and haemostasis Research on blood platelets and their interactions with other biological systems, such as the vessel wall, blood cells, and invading organisms Clinical manuscripts covering various topics including venous thrombosis, arterial disease, hemophilia, bleeding disorders, and platelet diseases Clinical manuscripts may encompass etiology, diagnostics, prognosis, prevention, and treatment strategies.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信